Carl Zeiss Meditec AG (VIE:AFX)
Austria
· Delayed Price · Currency is EUR | Market Cap | 2.37B |
| Revenue (ttm) | 2.20B |
| Net Income (ttm) | 120.61M |
| Shares Out | n/a |
| EPS (ttm) | 1.40 |
| PE Ratio | 19.68 |
| Forward PE | 17.10 |
| Dividend | 0.55 (2.08%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | n/a |
| Average Volume | 150 |
| Open | 27.22 |
| Previous Close | 27.32 |
| Day's Range | 27.02 - 27.22 |
| 52-Week Range | 25.38 - 70.45 |
| Beta | n/a |
| RSI | 38.34 |
| Earnings Date | Feb 12, 2026 |
About Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and p... [Read more]
Financial Performance
In fiscal year 2025, Carl Zeiss Meditec AG's revenue was 2.23 billion, an increase of 7.82% compared to the previous year's 2.07 billion. Earnings were 141.21 million, a decrease of -20.99%.
Financial StatementsNews
Carl Zeiss Meditec AG (CZMWF) Q1 2026 Earnings Call Highlights: Navigating Challenges with ...
Carl Zeiss Meditec AG (CZMWF) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic Localization and Strong Product Demand
Q1 2026 Carl Zeiss Meditec AG Earnings Call Transcript
Q1 2026 Carl Zeiss Meditec AG Earnings Call Transcript
Carl Zeiss Meditec AG (CZMWY) Q1 2026 Earnings Call Transcript
Carl Zeiss Meditec AG (CZMWY) Q1 2026 Earnings Call Transcript
Carl Zeiss Meditec AG Non-GAAP EPS of €0.03, revenue of €467M
Carl Zeiss Meditec AG 2026 Q1 - Results - Earnings Call Presentation
Carl Zeiss Meditec Slips To Loss In Q1, Revenue Down 4.8%; Pauses FY26 Outlook
JENA (dpa-AFX) - Carl Zeiss Meditec AG (CZMWF.PK, AFX.DE) Thursday said that it slipped to loss in the first quarter of 2026, impacted by lower revenue and a weak operating result. Additionally, t...
EQS-AFR: Carl Zeiss Meditec AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQS Preliminary announcement financial reports: Carl Zeiss Meditec AG / Preliminary announcement on the disclosure of financial statements Carl Zeiss Meditec AG: Preliminary announcement of the public...
Carl Zeiss Meditec: Why This Company Is A Good Choice For 2026
Carl Zeiss Meditec is rated a 'Strong Buy' with higher share price target, reflecting significant undervaluation and robust fundamentals. The company achieved over €2.2B in revenue (+7.5% YoY), strong...
Invesco Global Opportunities Fund Q3 2025 Performance Review
Invesco Global Opportunities Fund outperformed most in consumer staples due to stock selection and in real estate due to an underweight allocation. Stock selection in consumer discretionary, IT and ma...
Carl Zeiss Meditec AG (CZMWY) Q4 2025 Earnings Call Transcript
Carl Zeiss Meditec AG (CZMWY) Q4 2025 Earnings Call Transcript
Carl Zeiss Meditec AG (CZMWY) Discusses CEO Transition and Management Continuity Strategy Following Code of Conduct Investigation Transcript
Carl Zeiss Meditec AG (CZMWY) Discusses CEO Transition and Management Continuity Strategy Following Code of Conduct Investigation Transcript
Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors
Invesco International Small-Mid Company Fund outperformed most in the real estate and consumer staples sectors due to stock selection. The fund's underweight in real estate also added to relative retu...
Carl Zeiss Meditec: An Odd Reaction To 9M 2025 Earnings
Carl Zeiss Meditec is significantly undervalued after the 9M25 results, with the market overreaction creating a compelling entry point for long-term investors. Despite short-term margin pressures and ...
Carl Zeiss: The Results After 6M25 Are Encouraging For 2025-2027E
Carl Zeiss Meditec remains a high-quality medtech leader with strong moats in ophthalmic and microsurgery, despite recent margin pressures and Chinese market headwinds. Recent 6M25 results show encour...
Carl Zeiss Meditec AG (CZMWF) Q2 2025 Earnings Call Transcript
Carl Zeiss Meditec AG (OTCPK:CZMWF) Q2 2025 Earnings Conference Call May 13, 2025 4:30 AM ET Company Participants Sebastian Frericks - Director of Investor Relations Markus Weber - President and Chief...
Carl Zeiss Meditec: Recovery Seems Clear Enough
Carl Zeiss Meditec remains a "Buy" despite tariff concerns, with a revised price target of €110/share, reflecting geopolitical uncertainties and potential impacts on US-based revenues. The company sho...
Carl Zeiss: Why I Am So Positive
Carl Zeiss Meditec is a high-quality MedTech company with a strong market position, low debt, and significant long-term upside potential despite current macroeconomic challenges. The company's fundame...
My 3 Favorite European Stocks To Diversify Your Portfolio
Here is an emphasis on the importance of diversification in US-based investment portfolios to mitigate risks and enhance returns. The recommendation is to focus on sectors with strong growth potential...
Carl Zeiss: Significant Underperformance, Valuation At Multi-Year Lows
Carl Zeiss Meditec has seen a 30%+ decline due to earnings and margin drops, but remains a strong market leader with significant long-term upside. Despite current underperformance, the company's strat...
Carl Zeiss Meditec AG (CZMWF) Q3 2024 Earnings Call Transcript
Carl Zeiss Meditec AG (OTCPK:CZMWF) Q3 2024 Results Conference Call August 6, 2024 4:30 AM ET Company Participants Sebastian Frericks - Director of Investor Relations Markus Weber - CEO & Chairman of ...
Carl Zeiss Meditec: Slightly Better Valuation, Still A Significant Upside
Carl Zeiss Meditec has underperformed in the medtech field, but its long-term appeal remains intact. The company reported a decline in revenue and margins in the first half of 2023/2024, mainly due to...
Carl Zeiss Meditec AG (CZMWF) Q2 2024 Earnings Call Transcript
Carl Zeiss Meditec AG (OTCPK:CZMWF) Q2 2024 Earnings Conference Call May 8, 2024 4:30 AM ET Company Participants Sebastian Frericks - Head, IR Markus Weber - CEO Justus Wehmer - CFO Conference Call Pa...
Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market
ZEISS secures regulatory approvals to acquire D.O.R.C.; companies now shift focus to integration implementation, fueling world-class innovation, and driving market expansion strategy for ophthalmic me...
Carl Zeiss: We've Seen Outperformance, But I See More Upside Potential
Carl Zeiss Meditec has seen a significant increase in stock performance, up over 29% in less than 3 months. The company has shown strong top-line growth but a decline in EBIT and EBIT margin. Challeng...
Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)
Acquisition will extend the company's leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment JENA, Germany , Dec. 15, 2023 /PRNewswire/ -- Carl ...